Reduced SARS-CoV-2 vaccine-specific antibody response associated with high clozapine doses in schizophrenia spectrum disorders
High doses of clozapine (>350 mg/day) in patients with schizophrenia and schizoaffective disorders are associated with a diminished immune response to SARS-CoV-2 spike protein vaccination.
Authors
- Diego Palao (ORCID: https://orcid.org/0000-0002-3323-6568)
- Teresa Sagués
- Itziar Montalvo (ORCID: https://orcid.org/0000-0002-7320-5109)
- Patricia Pontón
- Antonio Berenguer (ORCID: https://orcid.org/0000-0002-3742-8161)
- Javier Labad (ORCID: https://orcid.org/0000-0003-2214-1886)
- Virginia Soria (ORCID: https://orcid.org/0000-0001-6412-6831)
- Raquel Rodríguez‐González (ORCID: https://orcid.org/0000-0003-4171-0263)
- Juan Francisco Delgado (ORCID: https://orcid.org/0000-0002-8751-8309)
- Germà Julià
- Albert Rodrigo-Parés
- Indira Bhambi
Institutions
- Universitat Autònoma de Barcelona (ES)
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Maresme Health Consortium (ES)
- Hospital de Sabadell (ES)
- Institute of Research and Innovation Parc Tauli (ES)
Publication Details
- Journal
- Brain Behavior & Immunity - Health
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1016/j.bbih.2025.101016
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Centres de Recerca de Catalunya
- Generalitat de Catalunya